A Phase II Intrapatient Open-Label Dose Escalation Trial of Defibrotide in Hematopoietic Cell Transplantation (HCT) Recipients With Sinusoidal Obstructive Syndrome (SOS) Post-HCT Associated With Either Renal and/or Pulmonary Dysfunction With Either Refractory or Progressive Disease Following Defibrotide Therapy
Latest Information Update: 28 Mar 2024
At a glance
- Drugs Defibrotide (Primary)
- Indications Hepatic veno-occlusive disease
- Focus Adverse reactions
Most Recent Events
- 22 Mar 2024 Status changed from not yet recruiting to recruiting.
- 06 Dec 2023 Planned initiation date changed from 1 Aug 2023 to 1 Dec 2023.
- 17 Aug 2023 New trial record